Table 1.
Lowering ability | Treatments |
---|---|
Extreme | Evolocumab 140 mg |
Alirocumab 75 mg | |
Alirocumab 150 mg | |
Very high | Potent statin + ezetimibe |
Atorvastatin 40–80 mg + ezetimibe 10 mg | |
Rosuvastatin 10–40 mg + ezetimibe 10 mg | |
High | High-potency statin |
Atorvastatin 40–80 mg | |
Rosuvastatin 20–40 mg | |
Medium-potency statin + ezetimibe | |
Simvastatin 20-40 mg + ezetimibe 10 mg | |
Pravastatin 40 mg + ezetimibe 10 mg | |
Lovastatin 40 mg + ezetimibe 10 mg | |
Fluvastatin 80 mg + ezetimibe 10 mg | |
Pitavastatin 2–4 mg + ezetimibe 10 mg | |
Atorvastatin 10–20 mg + ezetimibe 10 mg | |
Rosuvastatin 5 mg + ezetimibe 10 mg | |
Moderate | Medium-potency statin |
Atorvastatin 10–20 mg | |
Rosuvastatin 5–10 mg | |
Simvastatin 20–40 mg | |
Pravastatin 40 mg | |
Lovastatin 40 mg | |
Pitavastatin 2–4 mg | |
Fluvastatin XL 80 mg | |
Low-potency statin + ezetimibe | |
Simvastatin 10 mg + ezetimibe 10 mg | |
Pravastatin 20 mg + ezetimibe 10 mg | |
Lovastatin 20 mg + ezetimibe 10 mg | |
Fluvastatin 40 mg + ezetimibe 10 mg | |
Pitavastatin 1 mg + ezetimibe 10 mg |
Source: Escobar et al. (22).